Rostaporfin - TuHURA Biosciences
Alternative Names: PhotoPoint SnET2; Photrex; Purlytin; REM-001; REM-001 Therapy; Rostaporfin-PDT; Sn(IV) etiopurpurin; SnET2; SnET2-PDT; Tin ethyl etiopurpurinLatest Information Update: 23 Oct 2024
At a glance
- Originator Kintara Therapeutics
- Developer Miravant Medical Technologies; TuHURA Biosciences
- Class Antiglaucomas; Antihyperlipidaemics; Antineoplastics; Antipsoriatics; Eye disorder therapies; Heavy metals; Mesoporphyrins; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Breast cancer
- Phase I/II Basal cell cancer
- No development reported Age-related macular degeneration
- Discontinued Benign prostatic hyperplasia; Brain cancer; Coronary artery restenosis; Diabetic retinopathy; Glaucoma; Head and neck cancer; Kaposi's sarcoma; Lung cancer; Prostate cancer; Skin cancer
Most Recent Events
- 17 Oct 2024 Kintara Therapeutics has merged with TuHURA Biosciences to form TuHURA Biosciences
- 14 Feb 2024 Clinical trials in Breast cancer (Metastatic disease) (unspecified route)
- 12 Feb 2024 Kintara Therapeutics initiates phase II trial for Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (IV, infusion) (NCT05374915)